ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/biliary/advanced-metastatic
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gastrointestinal (Upper) / Biliary - Advanced/metastatic
12
trial(s) found.
NCT07873450
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-Human Phase 1/2 Dose Escalation and Treatment Optimization Study Evaluating Safety, Tolerability, and Preliminary Efficacy of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET (
FL-261-001
)
Cholangiocarcinoma
Colorectal cancer
Head and neck cancer
Non-small cell lung cancer
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07710885
Advanced
Phase 3
Recruiting
A Phase 3, Randomized-Controlled, Open-Label, Multi-Regional, International Study of Futibatinib (TAS-120) and Zimberelimab (AB122) in Combination With Gemcitabine Plus Cisplatin Versus Durvalumab or Pembrolizumab in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers (
FOENIX-BTC
)
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
antimetabolite
pan-FGFR inhibitor,irreversible
platinum-based antineoplastic agent
Biliary tract cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NA
NA
NCT07221253
Advanced
Phase 3
Recruiting
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02) (
AB02
)
anti-PD-L1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Biliary tract cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06760819
Advanced
Phase 2
Recruiting
A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (
panSOHO
)
EGFR/ERBB2 inhibitor,mutant-selective,non-covalent
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Endometrial cancer
NOT Biliary tract cancer
NOT Colorectal cancer
NOT Non-small cell lung cancer
NOT Urothelial carcinoma
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4215 - Southport - ICON Cancer Care
NCT06467357
Advanced
Phase 3
Recruiting
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (
DESTINY-BTC01
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-PD-L1 monoclonal antibody
antimetabolite
bispecific PD-1/TIGIT antibody
platinum-based antineoplastic agent
Biliary tract cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06441747
Advanced
Phase 2
Recruiting
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (
BIL-PPP
)
PARP1/2 inhibitor
anti-PD-L1 monoclonal antibody
Cholangiocarcinoma
Gallbladder cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2541 - Nowra - Shoalhaven District Memorial Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT06428409
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (
9999-02A
)
anti-Trop2 antibody-drug conjugate
Biliary tract cancer
Colorectal cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06219941
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01) (
D9800C00001
)
anti-CLDN18.2 antibody-drug conjugate
Biliary tract cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05727176
Advanced
Phase 2
Recruiting
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements (
FOENIX-CCA4
)
pan-FGFR inhibitor,irreversible
Cholangiocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (COMPLETED)
VIC
3004 - Melbourne, Southbank - Alfred Health (COMPLETED)
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (COMPLETED)
NCT05636215
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors (
CIBI354A101
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Biliary tract cancer
Breast cancer
Colorectal cancer
Gastric cancer
Gynaecological cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd (COMPLETED)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (COMPLETED)
VIC
3168 - Clayton - Monash Medical Centre (COMPLETED)
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (COMPLETED)
ACTRN12626001201369
Advanced
Phase 1 / Phase 2
Not yet recruiting
Phase 1/2 study on safety, tolerability and pharmacokinetics of Lutetium-177 (177Lu-ACT319) in patients with FAP-expressing pancreatic ductal adenocarcinoma, biliary tract carcinoma and other FAP-expressing solid tumours (
ACT319-101
)
Sturlimogene Erparepvec
bispecific-EGFR/CDH17 antibody-drug conjugate
cancer therapy
oncolytic herpes simplex virus
unknown drug class
Biliary tract cancer
Pancreatic adenocarcinoma
Solid tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (11)
Completed (1)
Not yet recruiting (1)
Recruitment Country and State
NSW (9)
WA (7)
QLD (7)
VIC (7)
SA (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (4)
Phase 2 (4)
Phase 3 (3)
Trial Type
Advanced (12)
Cancer Therapy Class
PD-1/PD-L1
42%
PD-1
33%
PD-L1
33%
ERBB2
25%
FGFR
17%
FGFR1
17%
FGFR1/2/3
17%
FGFR2
17%
FGFR3
17%
FGFR4
17%
TIGIT
17%
EGFR
8%
PARP
8%
Trop2
8%
CLDN18.2
8%
MET
8%
SMO
8%
VEGF
8%
Facility
3168 - Clayton - Monash Medical Centre (4)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
6150 - Murdoch - Fiona Stanley Hospital (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
2031 - Randwick - Scientia Clinical Research Ltd (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
6000 - Perth - Royal Perth Hospital (1)
NA
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
2109 - North Ryde - Macquarie University Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
4215 - Southport - ICON Cancer Care (1)
2139 - Concord - Concord Repatriation General Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
2541 - Nowra - Shoalhaven District Memorial Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
3002 - East Melbourne - Epworth Freemasons (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
6009 - Nedlands - One Clinical Research (1)
2031 - Randwick - Prince of Wales Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
Cancer Type
Cancer
Gastrointestinal cancer
Solid tumour
Biliary tract cancer
Hepatobiliary cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Cholangiocarcinoma
Thoracic cancer
Breast cancer
Gynaecological cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Gastroesophageal cancer
Head and neck cancer
Gastric cancer
Oesophageal cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Cervical cancer
Colorectal adenocarcinoma
Endometrial cancer
HPV-related cancer
HPV16-positive cancer
Urogenital cancer
Urothelial carcinoma
Viral-related cancer
Gallbladder cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Breast adenocarcinoma
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Ovarian cancer
Triple-negative breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy